US Senate panel narrowly tacks "pay-for-delay" ban onto a spending bill
This article was originally published in Scrip
Executive Summary
Drug makers may have been relieved by the US Senate's last-minute decision to drop several amendments from a war-funding bill that included a House provision banning "pay-for-delay" deals, but the issue has not died: on 29 July, a similar provision limiting generic drug makers' ability to accept money to settle patent disputes was cleared by the Senate Appropriations Committee.